Ontology highlight
ABSTRACT: Background
This phase 3 study evaluated the efficacy of new adjuvant chemotherapy (MFP), which intensified the mitomycin-C (MMC) plus short-term doxifluridine (Mf) for gastric cancer.Patients and methods
A total of 855 patients (424 in Mf, 431 in MFP) with pathological stage II-IV (M0) gastric cancer after D2 gastrectomy were randomly assigned to receive either Mf (MMC 20?mg?m(-2), followed by oral doxifluridine 460-600?mg?m(-2) per day for 3 months) or MFP (MMC 20?mg?m(-2), followed by oral doxifluridine 460-600?mg?m(-2) per day for 12 months with 6 monthly infusions of 60?mg?m(-2) of cisplatin) chemotherapy.Results
With a median follow-up of 6.6 years, there was no difference between the two groups in recurrence-free survival (RFS) (5-year RFS 61.1% in Mf and 57.9% in MFP; hazard ratio 1.10 (95% CI 0.89-1.35); P=0.39) and overall survival (OS) (5-year OS 66.5% in Mf and 65.0% in MFP; hazard ratio 1.11 (95% CI 0.89-1.39); P=0.33).Conclusion
Intensification of Mf adjuvant chemotherapy by prolonging the duration of oral fluoropyrimidine and adding cisplatin was safe but not effective to improve the survivals in curatively resected gastric cancer patients.
SUBMITTER: Kang YK
PROVIDER: S-EPMC3619263 | biostudies-literature | 2013 Apr
REPOSITORIES: biostudies-literature
Kang Y-K YK Chang H-M HM Yook J H JH Ryu M-H MH Park I I Min Y J YJ Zang D Y DY Kim G Y GY Yang D H DH Jang S J SJ Park Y S YS Lee J-L JL Kim T W TW Oh S T ST Park B K BK Jung H-Y HY Kim B S BS
British journal of cancer 20130228 6
<h4>Background</h4>This phase 3 study evaluated the efficacy of new adjuvant chemotherapy (MFP), which intensified the mitomycin-C (MMC) plus short-term doxifluridine (Mf) for gastric cancer.<h4>Patients and methods</h4>A total of 855 patients (424 in Mf, 431 in MFP) with pathological stage II-IV (M0) gastric cancer after D2 gastrectomy were randomly assigned to receive either Mf (MMC 20 mg m(-2), followed by oral doxifluridine 460-600 mg m(-2) per day for 3 months) or MFP (MMC 20 mg m(-2), foll ...[more]